



Edgar Filing: Akebia Therapeutics, Inc. - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On September 8, 2015, the Company issued a press release announcing results from its Phase 2 study of vadadustat (formerly AKB-6548) in dialysis patients with anemia related to chronic kidney disease. A copy of the press release is attached to this report as Exhibit 99.1. A copy of the presentation materials for the Akebia conference call and webcast on September 8, 2015 is attached to this report as Exhibit 99.2.

The information contained in this Item shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Akebia Therapeutics, Inc. dated September 8, 2015
99.2	Presentation Materials of Akebia Therapeutics, Inc. dated September 8, 2015

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKEBIA THERAPEUTICS, INC.**

/s/ John P. Butler

Name: John P. Butler

Title: President and Chief Executive Officer

Date: September 8, 2015

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Akebia Therapeutics, Inc. dated September 8, 2015
99.2	Presentation Materials of Akebia Therapeutics, Inc. dated September 8, 2015